Zoetis, Inc. Class A Stock News

Zoetis (ZTS) stock surged in intraday trading Tuesday after the company beat second-quarter revenue expectations and raised its full-year guidance.

Zoetis beat estimates on the top and bottom lines. Both the companion animal and livestock segments delivered solid growth.

Adjusted earnings per share topped analyst estimates. Net income fell 7% year over year to $624 million.

Animal healthcare company Zoetis raised its annual profit and revenue forecasts on Tuesday, betting on strong demand for its medicines and vaccines for pets.

After slowing in the prior two quarters, Zoetis earnings growth picked up and topped Q2 estimates early Tuesday.

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the second quarter of 2024 and raised its guidance for full year 2024. The company reported revenue of $2.4 billion for the second quarter of 2024, an increase of 8% compared with the second quarter of 2023. On an operational1 basis, revenue for the second quarter of 2024 in...

The SPDR S&P 500 ETF Trust posted a 1.21% gain in July, underperforming Vanguard's Dividend Appreciation Index Fund ETF Shares by +3.97%. The top 15 dividend growth stocks for August 2024 offer an average dividend yield of 1.49% and appear to be about 28% undervalued based on dividend yield theory. Since its inception in September 2020, the watchlist has achieved a 12.25% annualized return.

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that its Board of Directors has approved a multi-year $6 billion share repurchase program as part of its capital allocation plans. The demand for Zoetis' innovative and market-leading portfolio has enabled the company to execute its disciplined capital allocation strategy by reinvesting in growth op...